Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gamida Cell Ltd.GMDA · Entity 94655 | COO/CHIEF COMMERCIAL OFFICER | January 31, 2024 | February 02, 2024 |
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Director | February 18, 2026 | February 20, 2026 |
| TYME TECHNOLOGIES, INC.TYME · Entity 123718 | Chief Operating Officer | May 07, 2020 | May 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gamida Cell Ltd.
Report date January 31, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 702,981 |
Reported balance
After 2024-01-31 transaction · row 1
1 source rowRow 1 · 2024-01-31 · Grant · Acquired 480,319 · Balance 702,981 F1: Represents a restricted share unit award, and shall vest with respect to 33% of the RSUs, on each of July 31, 2024 and July 31, 2025, respectively, and with respect to 34% of the RSUs, on July 31, 2026. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit award, and shall vest with respect to 33% of the RSUs, on each of July 31, 2024 and July 31, 2025, respectively, and with respect to 34% of the RSUs, on July 31, 2026. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date.
Organogenesis Holdings Inc.
Report date February 18, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 239,073 |
Reported balance
After 2026-02-18 transaction · row 1
1 source rowRow 1 · 2026-02-18 · Grant · Acquired 48,828 · Balance 239,073 F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.
TYME TECHNOLOGIES, INC.
Report date May 07, 2020 · Filed May 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option - right to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2030-05-06 | Direct | 360,000 |
Reported balance
After 2020-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-07 · Grant · Acquired 360,000 · Balance 360,000 F1: This option vests over a four-year period in equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests over a four-year period in equal quarterly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 22:25 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 48,828 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000049 · form4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,073 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:43 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 49,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003214 · form4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,245 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2026. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:21 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 51,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004308 · form4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,670 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2025. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 16:35 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 480,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002306 · form4-02022024_090217.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · COO/CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 702,981 F1 · shares: Represents a restricted share unit award, and shall vest with respect to 33% of the RSUs, on each of July 31, 2024 and July 31, 2025, respectively, and with respect to 34% of the RSUs, on July 31, 2026. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:47 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 65,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004884 · form4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,650 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 19:55 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantEmployee Share Option (Right to Buy) · Derivative | 186,150 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-23-008562 · doc4.xml · derivative · entry 2 Korfin Michele Ilene · CIK 0001771664 · COO/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,150 Underlying: Ordinary Shares · 186,150 shares Expires 2033-02-07 F2 · derivative.exercise_date: 33% of the shares subject to the option award shall vest on each of August 8, 2023 and August 8, 2024, respectively, and 34% of the shares subject to the option award shall vest on August 8, 2025, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 19:55 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 92,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008562 · doc4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · COO/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,662 F1 · shares: Represents a restricted share unit award, and shall vest with respect to 33% of the RSUs, on each of August 8, 2023 and August 8, 2024, respectively, and with respect to 34% of the RSUs, on August 8, 2025. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:21 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 23,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-011683 · form4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,913 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on May 3, 2023. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 16:18 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantEmployee Share Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001209191-22-005908 · doc4.xml · derivative · entry 2 Korfin Michele Ilene · CIK 0001771664 · COO/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Ordinary Shares · 125,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on January 28, 2023, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 16:18 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 63,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005908 · doc4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · COO/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,672 Read SEC document |
| May 07, 2020 Filed May 18, 2020 17:55 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantEmployee Stock Option - right to buy · Derivative | 360,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0000899243-20-013426 · doc4.xml · derivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2030-05-06 F1 · derivative.exercise_date: This option vests over a four-year period in equal quarterly installments. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 13:20 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | PurchaseCommon Stock | 5,000 | $1.03 | $5,150.00 |
DisclosureSEC source: 0000899243-19-017155 · doc4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 07, 2019 Filed May 9, 2019 17:09 UTC | TYME TECHNOLOGIES, INC. TYME · Entity 123718 | GrantEmployee Stock Option - right to buy · Derivative | 375,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0000899243-19-012809 · doc4.xml · derivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2029-05-06 F1 · derivative.exercise_date: This option vests over a three-year period in equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.